These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39116700)

  • 21. Discrete choice experiment with duration versus time trade-off: a comparison of test-retest reliability of health utility elicitation approaches in SF-6Dv2 valuation.
    Xie S; Wu J; Chen G
    Qual Life Res; 2022 Sep; 31(9):2791-2803. PubMed ID: 35610406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valuing Child Health Utility 9D health states with a young adolescent sample: a feasibility study to compare best-worst scaling discrete-choice experiment, standard gamble and time trade-off methods.
    Ratcliffe J; Couzner L; Flynn T; Sawyer M; Stevens K; Brazier J; Burgess L
    Appl Health Econ Health Policy; 2011; 9(1):15-27. PubMed ID: 21033766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valuing SF-6D Health States Using a Discrete Choice Experiment.
    Norman R; Viney R; Brazier J; Burgess L; Cronin P; King M; Ratcliffe J; Street D
    Med Decis Making; 2014 Aug; 34(6):773-86. PubMed ID: 24025661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
    Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
    Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.
    Touré M; Sfairy SM; Bédard SK; McFadden N; Hanel R; Lemay F; He J; Pavic M; Poder TG
    Qual Life Res; 2024 Jun; 33(6):1605-1619. PubMed ID: 38642218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
    Xie S; Wang D; Wu J; Liu C; Jiang W
    Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do Portuguese and UK health state values differ across valuation methods?
    Ferreira LN; Ferreira PL; Rowen D; Brazier JE
    Qual Life Res; 2011 May; 20(4):609-19. PubMed ID: 21061071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set.
    Thomas S; Johnson JA; Xie F
    Qual Life Res; 2020 Nov; 29(11):3109-3118. PubMed ID: 32705459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of EuroQol Valuation Technology (EQ-VT) Designs to Generate National Value Sets: Learnings from the Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study.
    Jyani G; Yang Z; Sharma A; Goyal A; Stolk E; Purba FD; Grover S; Kaur M; Prinja S
    Med Decis Making; 2023 Aug; 43(6):692-703. PubMed ID: 37480281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method?
    Goossens ME; Vlaeyen JW; Rutten-van Mölken MP; van der Linden SM
    Pain; 1999 Mar; 80(1-2):365-75. PubMed ID: 10204750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in health utilities between cancer patients and the general population: The case of Quebec using the SF-6Dv2.
    Touré M; Poder TG
    Soc Sci Med; 2024 Jun; 351():117001. PubMed ID: 38805836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating the SF-6D value set for a population-based sample of Brazilians.
    Cruz LN; Camey SA; Hoffmann JF; Rowen D; Brazier JE; Fleck MP; Polanczyk CA
    Value Health; 2011; 14(5 Suppl 1):S108-14. PubMed ID: 21839880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new method for valuing health: directly eliciting personal utility functions.
    Devlin NJ; Shah KK; Mulhern BJ; Pantiri K; van Hout B
    Eur J Health Econ; 2019 Mar; 20(2):257-270. PubMed ID: 30030647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
    Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
    Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China.
    Ding N; Zhou H; Chen C; Chen H; Shi Y
    Appl Health Econ Health Policy; 2024 Jul; 22(4):555-568. PubMed ID: 38641755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Portuguese value set for the SF-6D.
    Ferreira LN; Ferreira PL; Pereira LN; Brazier J; Rowen D
    Value Health; 2010 Aug; 13(5):624-30. PubMed ID: 20230545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining health-related quality of life and health state utility values of recurrent urinary tract infections in women.
    Le Neveu M; Nicholson R; Agrawal P; Early M; Patterson D
    Int Urogynecol J; 2023 Aug; 34(8):1831-1835. PubMed ID: 36752848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
    Xie S; Wu J; Chen G
    Eur J Health Econ; 2024 Feb; 25(1):7-19. PubMed ID: 36709458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
    Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs).
    Brunner HI; Maker D; Grundland B; Young NL; Blanchette V; Stain AM; Feldman BM
    Med Decis Making; 2003; 23(4):314-22. PubMed ID: 12926581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.